This unlocks a new prospect for studying conivaptan in combination with tPA because the beneficial effects on BBB disruption may potentially minimize tPA-caused complications and could extend the therapeutic window for tPA administration after stroke. This evidence concerns the gene PLAT and stroke disorder.